Research programme: anti-L1 monoclonal antibodies - MediGene/German Cancer Research Center

Drug Profile

Research programme: anti-L1 monoclonal antibodies - MediGene/German Cancer Research Center

Latest Information Update: 30 Aug 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator German Cancer Research Center
  • Developer Celltrion; MediGene AG
  • Class Monoclonal antibodies
  • Mechanism of Action Cell adhesion molecule inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 17 Jul 2008 MediGene and Celltrion agree to co-promote and co-develop the products in Asia for Cancer
  • 17 Jul 2008 Products licensed to Medigene worldwide for the treatment of Cancer
  • 12 Mar 2008 Preclinical development for cancer is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top